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ABSTRACT
Objective: The 24-week Etanercept Assessment of Safety and
Effectiveness (EASE) study evaluated the effectiveness and
tolerability of continuous versus interrupted etanercept treat-
ment in patients with moderate to severe plaque psoriasis.
The objective of this analysis was to assess patient-reported
outcomes (PROs) and health-care resource utilization (HRU)
data from the EASE study.
Methods: Patients received open-label etanercept 50 mg
twice weekly for 12 weeks and then received either continued
or interrupted (single round of discontinuation and re-
treatment with etanercept) etanercept 50 mg once weekly for
the second 12 weeks. PROs included the following: 1) the
patient global assessments of psoriasis, joint pain, and itching
scores; 2) the Dermatology Life Quality Index; 3) the Medical
Outcomes Study Short Form 36 vitality domain; 4) the Beck
Depression Inventory; 5) the European Quality-of-Life
Group Feeling Thermometer; and 6) a patient satisfaction
survey. HRU was evaluated using the Economic Implications
of Psoriasis patient questionnaire.
Results: Continuous treatment with etanercept 50 mg twice
weekly for 12 weeks followed by 50 mg once weekly for
12 weeks produced sustained and clinically important
improvements in PROs and reductions in HRU. Reductions
in some outcome measures after treatment discontinuation at
week 12 were observed in the interrupted group; however,
most changes did not revert to baseline levels, consistent with
some residual clinical effect, and re-treatment produced
improvements similar to week 12 levels.
Conclusions: Continuous etanercept treatment provided
greater sustained improvements in PROs than interrupted
therapy; however, interrupting etanercept therapy, if needed,
has predictable and manageable effects.
Keywords: clinical trial, etanercept, health-care resource uti-
lization, psoriasis, quality of life, tumor necrosis factor.
Introduction
Psoriasis is a chronic, debilitating inﬂammatory
disease [1] that affects approximately 2% of the US
population [2] and has a profound effect on the lives of
patients and their family members. About 40% of
patients with psoriasis indicate that their condition is a
problem in their everyday lives [2]. Patients with more
severe disease and those with visible psoriatic plaques
report greater disability and lower health-related
quality of life than those with less severe disease or
those with plaques on less visible areas of the body
[2–4].
Psoriasis can have markedly negative consequences
on the physical and psychosocial functioning of those
affected, with patients often experiencing embarrass-
ment, self-consciousness, and negative body image as a
result of their condition [5]. Depression [6] and even
suicidal ideation [7] can also be important issues of
concern in patients with psoriasis. Furthermore, the
unique disabilities and emotional consequences asso-
ciated with this disease can affect work and social
activities [5,8,9]. In addition to the psychosocial
aspects of psoriasis, limited cost data suggest that
annual health-care resource utilization (HRU) for this
disease is considerable and represents a signiﬁcant
burden to patients and society [10].
Long-term treatment strategies are required to effec-
tively manage psoriasis [1]. Treatment that can provide
disease suppression or remission may offer patients
relief from the burden of psoriasis. The fully human
soluble tumor necrosis factor (TNF) receptor––FC
fusion protein etanercept––is indicated for moderate to
severe plaque psoriasis in the United States, Canada,
and Europe, and has been shown to be effective in
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relieving the skin symptoms and in improving health-
related quality of life in patients who have this disease
[11–13].
Most clinical studies of psoriasis therapies have
evaluated short-term efﬁcacy with continuous treat-
ment. In the real world, however, there are various life
circumstances (e.g., interruption in insurance coverage
or preparation for surgery) that may require intermit-
tent use of therapy. Therefore, it is important to deter-
mine the impact of intermittent use of agents for
psoriasis not only in terms of clinical efﬁcacy and
tolerability, but also on patient-reported outcomes
(PROs) and HRU as well. The Etanercept Assessment
of Safety and Effectiveness (EASE) study evaluated the
clinical efﬁcacy and tolerability of continuous versus
interrupted etanercept treatment in patients with mod-
erate to severe plaque psoriasis. The clinical results
from the EASE study have been reported elsewhere
[14]. This report presents PROs and HRU data from
the EASE study, with the hypothesis being that con-
tinuous treatment provides greater beneﬁts than inter-
rupted treatment, but that some level of beneﬁt is
maintained during interrupted therapy and beneﬁt is
regained with reinstitution of therapy.
Methods
The 24-week EASE study was a multicenter, random-
ized, open-label, phase 3b study of patients with pso-
riasis from 325 sites. The methodology for the EASE
study has been described in detail previously [14].
Patients were randomly assigned to one of two groups:
a continuous treatment group and an interrupted treat-
ment group as outlined in Figure 1. After treatment
with subcutaneous (SC) etanercept 50 mg twice
weekly (BIW) for the ﬁrst 12 weeks, patients in the
continuous group received uninterrupted SC etaner-
cept 50 mg once weekly (QW) through week 24. In the
interrupted group, responders at week 12, deﬁned as
those achieving a physician’s global assessment (PGA)
of psoriasis score of 2 (0 = clear, 5 = severe) and
improvement from baseline, discontinued therapy.
Upon relapse (i.e., loss of PGA responder status), treat-
ment with SC etanercept 50 mg QW was restarted at
either week 16 or 20 and continued through week 24.
Nonresponders in the interrupted group at week 12
received SC etanercept 50 mg QW from weeks 13 to
24, the same treatment received by those in the con-
tinuous treatment group.
Patient-reported outcomes included the following:
1) the patient global assessments (PtGA) of psoriasis,
joint pain, and itching scores, in which patients were
asked to rate these aspects of their psoriasis on a scale
from 0 (good or none) to 5 (severe); 2) the Dermatol-
ogy Life Quality Index (DLQI), a validated 10-item
outcome questionnaire designed to assess the patient’s
health-related quality of life [15], with total score
ranging from 0 to 30 points and higher scores indicat-
ing worse outcomes; 3) the Medical Outcomes Study
Short Form 36 (SF-36) vitality domain, a 4-item self-
Figure 1 Flow diagram of patient disposition. BIW, twice weekly; ETN, etanercept; QW, once weekly.
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administered questionnaire designed to assess the
patient’s perception of fatigue [16,17], with scores
ranging from 0 to 100 and lower scores indicating
more fatigue; 4) the Beck Depression Inventory (BDI),
a 21-item measure of mental status designed to assess
patients’ symptoms of depression, with scores ranging
from 0 to 63 and higher scores indicating more symp-
toms of depression; 5) the European Quality-of-Life
Group Feeling Thermometer (EuroQoL-FT), a visual
analog scale that assesses the patient’s health status,
with scores ranging from 0 (worst imaginable health
state) to 100 (best imaginable health state); and 6) a
patient satisfaction survey, a 10-item questionnaire
designed to assess patients’ satisfaction with their pso-
riasis treatment overall and for speciﬁc items (scaling,
itching, redness, tightness, bleeding, burning, fatigue,
work/school, and social activities). The hypothesis was
that interrupted treatment would have lower beneﬁts
on PRO measures than continuous etanercept treat-
ment at week 24.
Health-care resource utilization was evaluated
using the Economic Implications of Psoriasis patient
questionnaire, which assesses the impact of psoriasis
from an economic perspective, including health-related
outcomes (hospitalizations, emergency department or
urgent care clinic visits, and nondermatologist physi-
cian visits) and work-related outcomes (employment,
job responsibility changes because of psoriasis, and
sick days from work).
Data on PtGA of psoriasis, joint pain, and pruritus,
and on the DLQI, were collected at baseline and weeks
2, 4, 12, 16, 20, and 24. The BDI, EuroQoL-FT,
patient satisfaction survey, and Economic Implications
of Psoriasis patient questionnaire were assessed at
baseline and weeks 12 and 24. The SF-36 vitality
domain questionnaire was assessed at baseline and
weeks 2, 4, 12, and 24.
Analyses were performed on all patients who
received at least one dose of study drug using the
last-observation-carried-forward method to impute
missing data. Absolute improvements and the percent-
age improvements from baseline by visit in PROs were
summarized descriptively. In addition, 95% conﬁdence
intervals (CIs) were calculated by treatment group at
all postbaseline visits for the efﬁcacy end points. The
proportions of patients in the continuous and inter-
rupted arms were compared using a chi-square test.
For the economic implications of psoriasis outcome
measures, P-values for weeks 12 and 24 results relative
to baseline were calculated using McNemar’s test. The
following categories of HRU were collected: number
of days hospitalized in the last 3 months, number of
visits to an emergency room or urgent care clinic in the
last 3 months, and number of visits to a physician’s
ofﬁce other than a dermatologist in the last 3 months.
HRU data were skewed and were not normally distrib-
uted; therefore, 95% bootstrap bias corrected and
accelerated CIs were reported (bootstrap sample:
1000). P-values were based on the Wilcoxon signed
rank test comparing week 24 to baseline.
A post hoc analysis for PtGA and DLQI was per-
formed on patients in the interrupted group who
discontinued treatment at week 12 but restarted etan-
ercept treatment before week 24. This analysis was
performed to account for and to exclude patients in the
interrupted group who actually continued treatment
after week 12 (i.e., those who did not achieve
a PGA responder status). A second hypothesis was
generated post hoc, which postulated that among
PGA responders who discontinued and subsequently
resumed treatment, PROs would worsen from the dis-
continuation visit (week 12) to the re-treatment visit
(week 16 or 20) and revert back to baseline levels.
We were not able to assess the impact of discontinua-
tion and re-treatment on BDI, SF-36 vitality subscale,
or EuroQoL-FT because these outcomes were not
assessed at the re-treatment initiation visit.
Results
Patients
There were 1272 patients in the continuous therapy
group and 1274 in the interrupted therapy group who
were randomized and received at least one dose of
etanercept (N = 2546). Eighty-eight percent of patients
in the continuous group and 85% of patients in the
interrupted group completed the study. As per the
study design, not all patients in the interrupted group
discontinued therapy at week 12. Speciﬁcally, 357
patients (28%) in the interrupted group were PGA
nonresponders at week 12 and continued etanercept
therapy after the initial 12 weeks for the duration of
the study (i.e., through week 24). Four-hundred
eighty-eight patients discontinued and then restarted
treatment with etanercept (Fig. 1). Demographic char-
acteristics were well balanced between the two treat-
ment groups (Table 1).
Efﬁcacy and Safety
Efﬁcacy and safety results are reported elsewhere [14].
Brieﬂy, there were similar percentages of responders in
the continuous and interrupted groups at 12 weeks
(71.3% vs. 72.0%). Nevertheless, a signiﬁcantly
higher percentage of responders was observed at week
24 in the continuous group than in the interrupted
group (71.0% vs. 59.5%; P < 0.0001). Nearly one-
half (46.8%) of those who discontinued etanercept at
week 12 remained off therapy through week 24,
because they had not met the protocol-speciﬁed crite-
ria for relapse based on PGA responder status at each
of the subsequent evaluations. Etanercept was gener-
ally well tolerated in both treatment arms [14], with
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the safety results being consistent with those from
placebo-controlled trials of etanercept [11–13].
PROs and HRU in the Continuous versus Interrupted
Treatment Groups
PtGA of psoriasis, joint pain, and itching. Mean PtGA
of psoriasis scores were similar at baseline between the
continuous and interrupted arms (3.9 vs. 4.0). The
mean percentage improvement in PtGA of psoriasis
scores was comparable between the continuous and
interrupted groups at 12 weeks (Fig. 2a). These results
were maintained fromweeks 13 to 24 in the continuous
treatment group, whereas the percentage improvement
initially decreased in the interrupted group. A gradual
improvement was observed starting at week 20 after
patients had been allowed to reinitiate therapy.
Similar trends were observed in the PtGA of joint
pain (Fig. 2b) and itching (Fig. 2c), in which mean
scores were comparable between the two treatment
arms at baseline and after 12 weeks of therapy. Similar
to the PtGA of psoriasis, the percentage improvement
from baseline in the PtGA of itching decreased in the
interrupted group after week 12, but improved
between weeks 20 and 24. Notably, mean scores in the
PtGA of joint pain of the interrupted group returned to
baseline levels (Fig. 2b).
DLQI. Mean baseline DLQI scores were 12.2 and
12.5 for the continuous and interrupted groups,
respectively. At week 12, mean improvements in DLQI
scores were 66.9% and 67.7% from baseline, respec-
tively. DLQI improvement was maintained in the con-
tinuous group and diminished in the interrupted group
after week 12. At week 24, mean improvements in
DLQI scores from baseline were 66.6% and 54.0%,
respectively.
To assist in the clinical interpretation of these
results, we compared these data using a banding
method proposed by Hongbo et al. [18], which corre-
lated speciﬁc DLQI scores with the effect of psoriasis
on patients’ lives (DLQI scores 0–1 = no effect;
DLQI scores 2–5 = small effect; DLQI scores
6–10 = moderate effect; DLQI scores 11–20 = very
large effect; DLQI scores 21–30 = extremely large
effect). Based on this method, etanercept therapy pro-
vided clinically important improvements in patients’
health-related quality of life. Whereas psoriasis had a
very large effect on patients’ lives in both groups at
baseline (mean scores 12.2 and 12.5 for the continuous
and interrupted groups, respectively), the disease had a
small effect at week 12 (mean scores 3.5 and 3.7,
respectively) and week 24 (mean scores 3.6 and 5.2,
respectively). Subscale results (symptoms and feelings,
daily activities, leisure, work and school, personal rela-
tionships, treatment) were generally similar to those
observed with the DLQI total score analysis.
SF-36 vitality domain. Mean baseline SF-36 vitality
domain scores were similar in both treatment groups
(53.7 for the continuous group and 54.1 for the inter-
rupted group). At week 12, there was a mean percent-
age improvement from baseline of 76.5% (9.2 points)
in the continuous group and 74.0% (8.4 points) in the
interrupted group. Improvements in these scores
were generally maintained in both groups at week
24 (72.8% [9.6 points] and 70.6% [7.6 points],
respectively).
BDI. The mean BDI scores at baseline were 8.1 and
8.3 in the continuous and interrupted treatment arms,
respectively. Mean BDI scores improved from baseline
to week 12 by about 29% in both groups (28.8% and
29.3%, respectively). The improvements were gener-
ally maintained in the continuous (28.6% [95% CI
23.1–34.1]) and interrupted groups (23.9% [95% CI
18.6–29.1]) at week 24.
EuroQoL-FT. Mean EuroQoL-FT scores improved
from baseline (74.7 for the continuous arm and 74.5
Table 1 Baseline demographics and disease characteristics
Characteristics Continuous group Interrupted group
Number of patients 1272 1274
Mean (SD) age (year) 45.8 (13.6) 44.9 (13.6)
Men (%) 63 62
White (%) 84 86
Median (range) weight (kg) 87.4 (41.4–218.3) 87.8 (43.5–205.2)
Median (range) height (cm) 173 (130–203) 173 (127–203)
Median (range) duration of psoriasis (year) 16.3 (0.0–63.0) 16.4 (0.0–74.5)
Median (range) affected body surface area (%) 20.0 (10.0–100.0) 20.0 (10.0–100.0)
Physician global assessment of psoriasis, n (%)
Clear 0 (0) 0 (0)
Almost clear 18 (1.4) 16 (1.3)
Mild 191 (15.0) 223 (17.5)
Moderate 683 (53.7) 657 (51.6)
Marked 313 (24.6) 313 (24.6)
Severe 67 (5.3) 65 (5.1)
Patients with at least one prior systemic psoriasis therapy (%) 49 51
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for the interrupted arm) to week 12 in both treatment
groups (by 49.0% [8.0 points] and 38.0% [8.2 points]
in the continuous and interrupted groups, respec-
tively). These improvements were maintained in both
groups at week 24 (52.9% [95% CI 21.4–84.4] and
36.5% [95% CI 20.0–53.0], respectively).
Patient satisfaction survey. At baseline, more than
60% of patients in both treatment groups indicated
that they were not at all satisﬁed with their previous
or current psoriasis treatment, while only 12% of
patients in both treatment groups indicated that they
were either “very much” or “a lot” satisﬁed with their
psoriasis treatment. After 12 weeks of etanercept treat-
ment, 52.5% and 49.0% of patients in the continuous
and interrupted groups, respectively, indicated that
they were “very much” satisﬁed with their psoriasis
treatment. Moreover, 77.6% and 77.4% of patients,
respectively, rated satisfaction with their psoriasis
therapy in the past week at “very much” or “a lot.”
These levels of satisfaction were largely maintained
through week 24 in the continuous treatment group,
although somewhat reduced for some measures in the
interrupted group (69.1% vs. 57.6% rated their satis-
faction with treatment as “very much” or “a lot” at
week 24). Results for the other questions in the satis-
faction survey generally followed a similar trend to the
result for overall satisfaction with treatment.
Burden of illness. HRUwas signiﬁcantly reduced from
baseline with etanercept treatment in continuous and
intermittent treatment groups, respectively, at week 12
in terms of the proportions of patients requiring hos-
pitalization (5.4% vs. 3.6% [P = 0.0106] and 5.7% vs.
3.2% [P = 0.0034]), patients requiring emergency
department or urgent care clinic visits (11.2% vs.
8.2% [P = 0.0061] and 12.3% vs. 7.8% [P = 0.0002]),
and patients requiring nondermatologist ofﬁce visits
(49.8% vs. 39.5% [P < 0.0001] and 51.8% vs. 37.2%
[P < 0.0001]). Improvements were generally main-
tained at week 24, with no signiﬁcant difference
between the continuous and interrupted groups.
Figure 3 shows the mean 24-week reductions in the
number of days hospitalized, number of emergency
department or urgent care clinic visits (P < 0.005 vs.
baseline for both continuous and intermittent groups),
and number of nondermatologist ofﬁce visits (P <
0.005 vs. baseline for both continuous and intermit-
tent groups).
The percentages of gainfully employed patients
were similar for both groups at baseline (88% for both
groups) and at week 12 (no signiﬁcant change from
baseline to week 12: 87% for both groups). Neverthe-
less, an increase in the percentage of patients working
for pay was noted at week 24 relative to baseline for
both groups (92.6% and 91.9% for continuous and
intermittent groups, respectively; both P  0.0001).
The percentages of patients who had to change job
responsibilities because of their psoriasis were
improved from baseline to week 12 in both treatment
groups and continued to improve at week 24, reaching
statistical signiﬁcance (3.8% at baseline to 1.7% at
week 24 [P = 0.001] for the continuous group and
3.5% at baseline to 1.9% at week 24 [P = 0.023] for
(a)
(b)
(c)
Figure 2 Mean percentage improvement from baseline in the patient
global assessment of (a) psoriasis, (b) joint pain, and (c) itching. PtGA,
patient global assessment; SEM, standard error of the mean.
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the interrupted group). The proportions of patients
who reported no sick days off from work in the pre-
vious month also improved with either continuous or
interrupted etanercept therapy: 70.8% vs. 72.6% at
baseline, 76.8% vs. 78.3% at week 12, and 74.5% vs.
75.3% at week 24.
Analysis of patients who discontinued and then
restarted etanercept therapy. For the prospective
analysis, the interrupted treatment group contained
patients who continued etanercept therapy (nonre-
sponders at week 12) and those who discontinued
treatment (responders at week 12). To evaluate the
PROs in the responders who discontinued therapy but
then experienced a relapse and were re-treated, a post
hoc analysis was conducted for PtGA of psoriasis and
DLQI. A total of 488 patients (53%) who discontin-
ued therapy at week 12 restarted etanercept therapy at
week 16 (n = 329) and week 20 (n = 159) (Fig. 1).
Mean PtGA of psoriasis and DLQI scores for this
subgroup decreased (improved) from baseline (mean
PtGA score 4.0; mean DLQI score 12.2) to week 12
(mean PtGA score 1.4; mean DLQI score 3.1) but
increased at the re-treatment visit (mean PtGA score
2.7; mean DLQI score 7.0; both P < 0.001 from base-
line) (Fig. 4). The mean change from discontinuation
at week 12 to the re-treatment visit was less than the
minimal clinically important difference of ﬁve units for
the DLQI [19]. About one-third of patients (167 of
472 patients with evaluable DLQI data) experienced a
decline in DLQI score of greater than ﬁve units after
treatment withdrawal. Furthermore, according to the
banding DLQI model proposed by Hongbo et al. [18]
that was described earlier, etanercept also had a clini-
cally important effect on these patients. Although pso-
riasis had a very large effect on patients’ lives at
baseline (mean score 12.2), the impact of the disease
was small at week 12 (mean score 3.1) and moderate
at re-treatment (mean score 7.0).
Discussion
Psoriasis is associated with a signiﬁcant burden of
illness that has a major impact on PROs and HRU
[10]. In this study, both continuous and interrupted
etanercept treatment improved patient well-being and
reduced HRU. Measures of PtGA of psoriasis, joint
pain, and itching all were markedly improved and
sustained with continuous etanercept treatment,
although improvement initially declined in the inter-
rupted group during the discontinuation phase of the
study but was gradually regained after re-treatment,
with the exception of joint pain. Measures of health-
related quality of life, depression, and vitality were
Figure 3 Mean reduction from baseline in
health-care resource utilization (HRU) at week
24. Bootstrap methodology (bootstrap sample:
1000) was used to account for non-normally
distributed data. *P < 0.0005 vs. baseline. CI,
conﬁdence interval.
(a)
(b)
Figure 4 Values for (a) the patient global assessment (PtGA) of psoriasis
and (b) the Dermatology Life Quality Index (DLQI) at week 12 and at
re-treatment visit for week-12 responders who discontinued and then
restarted etanercept therapy. *P < 0.001 vs. baseline. SEM, standard error
of the mean.
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improved with treatment in both groups. These results
are important because nearly 80% of patients with
severe psoriasis indicate that their condition has a
negative impact on their lives (including profound
emotional, social, and physical impact on quality of
life) [8].
Patients were also satisﬁed with etanercept treat-
ment, although this declined somewhat in the inter-
rupted group during the discontinuation phase of the
study. Indeed, the proportion of patients who indicated
that they were not at all satisﬁed with their psoriasis
treatment in both groups decreased from more than
60% at baseline to less than 10% at week 12, and the
percentage of patients who were “very much” or “a
lot” satisﬁed with their treatment increased from
approximately 12% at baseline to nearly 80% at week
12. This is a substantial improvement during the
course of therapy and an important outcome as many
patients are not satisﬁed with their psoriasis treatment.
A National Psoriasis Foundation (NPF) survey of their
patient membership found that 49% of patients were
either only somewhat or not at all satisﬁed with their
psoriasis treatments, and 32% of those with severe
psoriasis indicated that their treatment was not aggres-
sive enough [8]. By design, the NPF survey captured a
much broader patient population than those enrolled
into this present study (limited to patients with 10%
body surface area).
Health-related quality-of-life results in this study
are consistent with those from randomized, placebo-
controlled clinical trials [11,20–23]. Mean improve-
ment in DLQI scores at week 12 was approximately
70% in a previous study of patients receiving etaner-
cept 50 mg QW and 50 mg BIW. At 24 weeks, mean
improvements in DLQI scores were approximately
65% in both dosing arms [20]. In this study, we
reported about 67% improvement from baseline in the
DLQI at weeks 12 and 24 in the continuous treatment
group, and about 70% and 54% improvements in the
interrupted group at weeks 12 and 24, respectively.
Improvements in the DLQI and other assessments con-
ﬁrmed our initial hypothesis that interrupted treatment
would have lower beneﬁts on PRO than continuous
etanercept treatment at week 24.
Because not all patients randomized to the inter-
rupted group actually discontinued treatment with
etanercept, it was important to determine how patients
who withdrew from etanercept at week 12 fared with
respect to their PtGA and DLQI responses after dis-
continuation and before re-treatment. Health-related
quality-of-life measures did decrease on discontinua-
tion, but did not reach baseline levels. Therefore, the
post hoc hypothesis that health-related quality-of-life
measures would decline to baseline levels on abrupt
discontinuation of etanercept was not supported. This
may be due in part to the longevity of an etanercept
effect, and that in addition to relieving the signs and
symptoms of psoriasis, etanercept has been shown to
improve fatigue and symptoms of depression in a
randomized, double-blind, phase 3 study [21]. The
results of this post hoc analysis were consistent with
the overall results in the interrupted treatment group
and suggest that if patients respond well to etanercept
treatment but require a holiday period, they may dis-
continue treatment and continue to beneﬁt from
re-treatment at a later time. This clinical observation is
supported in the literature for etanercept and other
biologics in the treatment of psoriasis [24–26] and for
topical corticosteroid treatment of atopic dermatitis
[27]. Nevertheless, analysis of DLQI scores indicated
that continuous therapy provided more sustained
improvements in skin-related health-related quality of
life than interrupted therapy, which led to some ﬂuc-
tuations in patients’ health-related quality of life.
This is the ﬁrst study to report the effect of etaner-
cept treatment on work-related outcomes in patients
with moderate to severe plaque psoriasis. Patients with
well-controlled psoriasis miss fewer days of work, and
their psoriasis has less impact on their job responsibi-
lities while in the workplace. Continuous and inter-
rupted therapy with etanercept also signiﬁcantly
reduced the proportions of patients requiring hospital-
ization, emergency department visits or urgent medical
attention, and nondermatologist physician visits.
Although costs were not included in the analysis,
improvements in these parameters have the potential
to reduce direct and indirect medical costs associated
with psoriasis. A formal economic analysis is war-
ranted to compare cost effectiveness of the continuous
versus intermittent treatment.
One important study limitation is the open-label
study design, which introduces the potential for a
treatment outcome bias (i.e., patients knew that they
were being treated and therefore expected a positive
effect). Nevertheless, data from this study are in line
with observations from placebo-controlled trials of
etanercept in psoriasis. Another consideration is that
the changes in work-related outcomes and HRU may
have been due in part to the increased monitoring and
clinician oversight that accompanies a clinical trial.
These results will need to be veriﬁed in further trials.
And ﬁnally, patients in the interrupted treatment group
may have required additional time to experience the
full effects of etanercept after discontinuation and
re-treatment.
Continuous treatment with etanercept 50 mg BIW
for 12 weeks followed by 50 mg QW for 12 weeks
provided sustained and clinically important improve-
ments in PROs and reductions in HRU. Although there
were reductions in some outcome measures after treat-
ment discontinuation at week 12 in the interrupted
group, most changes did not revert to baseline levels,
and improvements similar to week 12 levels were
observed on re-treatment. In conclusion, continuous
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treatment of etanercept does provide greater improve-
ments in PROs than does interrupted treatment.
Should the need arise to interrupt etanercept therapy,
one can expect a slow reduction in PRO and HRU
beneﬁts and reclaimed beneﬁt after reinstituting etan-
ercept treatment.
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